Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP-G2-044 + anti-PD-1 therapy (Novita Pharmaceuticals)
- Development stage
- Unknown
- Lead developer
- Novita Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
NP-G2-044 + anti-PD-1 therapy is an investigational combination treatment consisting of NP-G2-044, a first-in-class small-molecule fascin inhibitor, and a standard-of-care anti-PD-1 monoclonal antibody. NP-G2-044 targets fascin, an actin-bundling protein that is highly expressed in many metastatic tumors and is essential for tumor cell motility and migration. By inhibiting fascin, NP-G2-044 aims to block the metastatic spread of cancer cells and potentially enhance the activity of dendritic cells within the tumor microenvironment. The addition of an anti-PD-1 therapy, which blocks the Programmed Cell Death Protein 1 checkpoint, is intended to revitalize the immune system's ability to recognize and destroy tumor cells. This combination is currently being evaluated in Phase 2 clinical trials for patients with advanced or metastatic solid tumor malignancies, including those who have previously progressed on or are resistant to prior anti-PD-1 therapies.
- Other names
- NP-G2-044 in combination with anti-PD-1 therapyNP-G-2-044 in combination with anti-PD-1 therapyNP-G 2-044 in combination with anti-PD-1 therapy
02
Targets
FSCN1PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on NP-G2-044 + anti-PD-1 therapy (Novita Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NP-G2-044 + anti-PD-1 therapy (Novita Pharmaceuticals).